Stockreport

Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome [Yahoo! Finance]

Neurogene Inc.  (NGNE) 
PDF Interim safety data presented at the International Rett Syndrome Foundation (IRSF) ASCEND Summit NEW YORK, June 18, 2024 BUSINESS WIRE )--Neurogene Inc. (Nasdaq: NGNE [Read more]